MTRI — Mentari Therapeutics Share Price
Last trade - 00:00- $802.28m
- $801.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 978.16 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -224.38% | ||
| Operating Margin | -1440.26% | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.09 | 4.14 | 4.6 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mentari Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the prevention of migraine. The Company's lead programs are MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-pituitary adenylate cyclase-activating polypeptide (PACAP) and anti-calcitonin gene-related peptide (CGRP) bispecific antibody with the potential to deliver efficacy for people with incomplete response to existing therapies. It is advancing a robust portfolio of potentially therapies that target validated pathways in migraine biology. MT-001 and MT-002, both target pituitary adenylate cyclase-activating polypeptide, an emerging and clinically validated target. MT-001, an investigational monoclonal antibody with potential for efficacy and convenient, infrequent subcutaneous dosing. MT-002 is an investigational bispecific antibody targeting both PACAP and CGRP that is designed for infrequent subcutaneous dosing.
Directors
- Gregory Divis PRE (60)
- Brett Hagen CFO (53)
- Jerad Seurer GCN (53)
- Julianne Bruno NEC (40)
- Michelle Pernice IND (38)
- Laura Sandler IND (49)
- Todd Shegog IND (61)
- Last Annual
- June 30th, 2026
- Last Interim
- September 30th, 2026
- Incorporated
- November 6th, 2026
- Public Since
- June 21st, 2001
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 51,560,364
- Address
- 221 Crescent Street, WALTHAM, 02453
- Web
- https://mentaritx.com
- Phone
- +1 7818875080
- Contact
- Colin Clancy
- Auditors
- CBIZ CPAs P.C.
Latest News for MTRI
Upcoming Events for MTRI
InMed Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2027 InMed Pharmaceuticals Inc Earnings Release
Q3 2027 InMed Pharmaceuticals Inc Earnings Release
Similar to MTRI
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 12:02 UTC, shares in Mentari Therapeutics are trading at $18.60. This share price information is delayed by 15 minutes.
Shares in Mentari Therapeutics last closed at $18.60 and the price had moved by +2.76% over the past 365 days. In terms of relative price strength the Mentari Therapeutics share price has underperformed the S&P500 Index by -8.48% over the past year.
The overall consensus recommendation for Mentari Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMentari Therapeutics does not currently pay a dividend.
Mentari Therapeutics does not currently pay a dividend.
Mentari Therapeutics does not currently pay a dividend.
To buy shares in Mentari Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.60, shares in Mentari Therapeutics had a market capitalisation of $802.28m.
Here are the trading details for Mentari Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MTRI
Based on an overall assessment of its quality, value and momentum Mentari Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mentari Therapeutics is $40.60. That is 118.29% above the last closing price of $18.60.
Analysts covering Mentari Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.86 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mentari Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +184.48%.
As of the last closing price of $18.60, shares in Mentari Therapeutics were trading +26.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mentari Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mentari Therapeutics' management team is headed by:
- Gregory Divis - PRE
- Brett Hagen - CFO
- Jerad Seurer - GCN
- Julianne Bruno - NEC
- Michelle Pernice - IND
- Laura Sandler - IND
- Todd Shegog - IND